|
|
|
Stem Cell Related Patent Number US6982082
| Title: | Gene therapy by cell specific targeting | | Inventors: | Schreiber, Stuart L.; Boston, MA, USA
Belshaw, Peter J.; Somerville, MA, USA
Crabtree, Gerald; Woodside, CA, USA | | Summary: | Described herein is a novel polypeptide interaction trap assay which employs the use of prokaryotic host cells in producing fusion proteins which activate reporter genes. Central to the invention is a modified cyclosporin A and a modified, genetically engineered version of its receptor, cyclophilin. Methods are disclosed by which host-versus-graft disease following blood marrow transplantation is treated by transfected stem cells which are introduced into a patient such that modified cyclophilin is expressed and modified cyclosporin A is administered to the patient as necessary. The result is a method for inhibiting the proliferation of genetically engineered T cells comprising a nucleic acid encoding a mutated macrolide binding protein (MBP) selected from an FK506-binding protein (FKBP), cyclophilin, calcineurin, and FKBP:rapamycin associated protein (FRAP). Therapeutic applications emphasize intervention in host-versus-graft disease. | | Abstract: | This invention is directed to a modified cyclosporin A and to a modified, genetically engineered version of its receptor, cyclophilin. This invention is further directed to a method for treating host versus graft disease following blood marrow transplantation by transfecting stem cells so that after introduction into a patient the stem cells will express the modified cyclophilin, and, as necessary, administer the modified cyclosporin A to the patient. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6982082 | | Application Number: | US1997000922240 | | Date Filed: | 27/08/1997 | | Date Published: | 03/01/2006 | | Assignee: | President and Fellows of Harvard College, Cambridge, MA, USA
Board of Trustees of the Leland Stanford Junior University, Stanford, CA, USA |
|
|
